Autologous Blood Products in Ridge Preservation

April 8, 2026 updated by: Mustafa Tunali, Çanakkale Onsekiz Mart University

Clinical, Radiological, and Ultrasonographic Evaluation of Autologous Blood Products in Alveolar Ridge Preservation: A Randomized Controlled Clinical Trial

This randomized controlled clinical trial aims to evaluate the clinical, radiographic, and ultrasonographic outcomes of alveolar ridge preservation using autologous blood products following tooth extraction.

After tooth extraction, dimensional changes occur in both hard and soft tissues, which may negatively affect future implant or prosthetic treatments. This study investigates whether the application of Titanium Platelet-Rich Fibrin (T-PRF), combined with injectable Platelet-Rich Fibrin (i-PRF), can improve healing and reduce tissue changes.

In this study, tooth extraction will be performed under local anesthesia using minimally invasive techniques. Autologous blood will be collected from the patient and processed by centrifugation to obtain T-PRF and i-PRF. The prepared materials will be applied to the extraction socket and stabilized with sutures. Healing will be monitored through clinical examinations, radiographic imaging, and ultrasonographic evaluations over a 6-month follow-up period.

Possible risks include pain, bleeding, infection, and temporary discomfort, all of which are manageable with standard clinical care.

The study is expected to contribute to the development of biologically based, minimally invasive treatment approaches that enhance tissue healing and support future dental treatments.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Systemically healthy individuals with no medical conditions that could interfere with periodontal treatment, tooth extraction, or wound healing
  • Absence of systemic diseases affecting blood coagulation and no use of anticoagulant medications
  • No history of blood-borne infectious diseases
  • Non-smokers
  • Age ≥18 years
  • Patients requiring extraction of a single-rooted tooth in the maxilla or mandible
  • Availability of a pre-existing CBCT scan of the planned extraction site
  • Extraction site suitable for implant placement

Exclusion Criteria:

  • Presence of systemic diseases that may affect periodontal treatment, tooth extraction, wound healing, or increase the risk of complications
  • Presence of bleeding or coagulation disorders, or use of anticoagulant therapy
  • Presence of blood-borne infectious diseases
  • Smoking habit
  • Age <18 years
  • Psychological or mental conditions that may affect compliance with treatment or study participation
  • Extraction sites not suitable for implant placement
  • History of previous surgical intervention or compromised healing in the extraction site
  • Pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: control
Active Comparator: test
Procedure: Autologous Titanium Platelet-Rich Fibrin with Injectable PRF Application

Following atraumatic tooth extraction under local anesthesia, autologous blood will be collected from the patient. Titanium platelet-rich fibrin (T-PRF) will be prepared by centrifugation of blood in titanium tubes, and injectable platelet-rich fibrin (i-PRF) will be obtained using a low-speed centrifugation protocol.

The prepared i-PRF will be injected into the T-PRF membrane to create a combined autologous fibrin construct. This material will then be placed into the extraction socket to support clot stability and tissue regeneration, and the site will be sutured for stabilization.

This approach combines the dense fibrin structure of T-PRF with the biological activity of i-PRF, aiming to enhance angiogenesis, soft and hard tissue healing, and preservation of alveolar ridge dimensions.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Horizontal Bone Width Change (CBCT Analysis)
Time Frame: 6 month
Evaluation of horizontal bone width in millimeters at standardized levels (1 mm, 3 mm, and 5 mm from the alveolar crest) using CBCT at baseline (immediately after extraction) and 6 months
6 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Çanakkale Onsekiz Mart University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2026

Primary Completion (Estimated)

November 1, 2026

Study Completion (Estimated)

January 1, 2027

Study Registration Dates

First Submitted

April 1, 2026

First Submitted That Met QC Criteria

April 8, 2026

First Posted (Actual)

April 15, 2026

Study Record Updates

Last Update Posted (Actual)

April 15, 2026

Last Update Submitted That Met QC Criteria

April 8, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • OGU-EC-07-25
  • 2024-KAEK-15 (Other Identifier: Turkish Medicines and Medical Devices Agency (TİTCK))

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ridge Preservation

Clinical Trials on Autologous Titanium Platelet-Rich Fibrin with Injectable PRF Application

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe